- Home
- TRMK vs MYGN Comparison
TRMK vs MYGN Comparison
Compare TRMK & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMK
- MYGN
- Stock Information
- Founded
- TRMK 1889
- MYGN 1991
- Country
- TRMK United States
- MYGN United States
- Employees
- TRMK N/A
- MYGN N/A
- Industry
- TRMK Major Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TRMK Finance
- MYGN Health Care
- Exchange
- TRMK Nasdaq
- MYGN Nasdaq
- Market Cap
- TRMK 2.1B
- MYGN 2.0B
- IPO Year
- TRMK 1987
- MYGN 1995
- Fundamental
- Price
- TRMK $35.47
- MYGN $12.57
- Analyst Decision
- TRMK Hold
- MYGN Hold
- Analyst Count
- TRMK 5
- MYGN 12
- Target Price
- TRMK $34.60
- MYGN $23.92
- AVG Volume (30 Days)
- TRMK 288.3K
- MYGN 1.0M
- Earning Date
- TRMK 01-28-2025
- MYGN 02-25-2025
- Dividend Yield
- TRMK 2.60%
- MYGN N/A
- EPS Growth
- TRMK 111.96
- MYGN N/A
- EPS
- TRMK 3.30
- MYGN N/A
- Revenue
- TRMK $555,586,000.00
- MYGN $823,600,000.00
- Revenue This Year
- TRMK N/A
- MYGN $13.73
- Revenue Next Year
- TRMK $4.13
- MYGN $4.34
- P/E Ratio
- TRMK $62.00
- MYGN N/A
- Revenue Growth
- TRMK N/A
- MYGN 12.15
- 52 Week Low
- TRMK $25.24
- MYGN $12.17
- 52 Week High
- TRMK $40.73
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- TRMK 49.40
- MYGN 32.55
- Support Level
- TRMK $34.65
- MYGN $12.17
- Resistance Level
- TRMK $35.94
- MYGN $15.08
- Average True Range (ATR)
- TRMK 0.95
- MYGN 0.80
- MACD
- TRMK 0.14
- MYGN -0.03
- Stochastic Oscillator
- TRMK 79.74
- MYGN 13.75
About TRMK Trustmark Corporation
Trustmark Corp is a s a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee and Texas. Its principal products and services include, Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services and others. The company is managed along three operating segments; General Banking, Wealth Management and Insurance. The General Banking segment which generates the majority of the revenue provides all traditional banking products and services, including loans, deposits and also consists of internal operations.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.